Special Issue

Peptide-Based Vaccines: Current Progress and Future Challenges

Message from the Guest Editors

Vaccines are perhaps the most successful discovery of biomedical sciences, and prevent approximately 2-3 million deaths annually. Representing a step forward, peptide-based vaccines have revolutionized disease management and prevention against various infectious diseases, including viral, bacterial, fungal, and parasitic diseases. Peptide-based vaccines (also called subunit vaccines) consist of immunogenic components of infectious agents or disease-associated epitopes. These vaccines aim to impart protective immunity with prior exposure of pathogen-specific epitopes to the host's protective immune cells. The major challenge is to find a pathogen-specific epitope that could direct the immune response against the pathogen. In contrast, while developing vaccines against self-antigens to cure various chronic and autoimmune diseases, the immune system plays a crucial role in suppressing response to self-antigens. This Special Issue invites quality research works exploring peptide-based vaccine development against infectious, chronic, and autoimmune diseases for publication.

Guest Editors

Dr. Shailendra Kumar Verma

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA

Dr. Rajan Kumar Pandey

Department of Medical Biochemistry and Biophysics, Karolinska Institute, 17177 Stockholm, Sweden

Deadline for manuscript submissions

closed (20 June 2023)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/143244

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

